Overview

Phase I of VLT-015 in Patients With Schizophrenia

Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Valentech LLC